RA Capital Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
RA Capital Management's ACRS Position: Q3 2026 in Review
RA Capital Management held its Aclaris Therapeutics (ACRS) position steady in Q3 2026 at 12,723,026 shares worth $66.9M. The position accounts for 0.67% of the portfolio, ranked #32.
RA Capital Management first reported a position in ACRS in Q4 2015 and has held it in 16 quarters since. The position peaked at $69.3M in Q4 2022. 163 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- RA Capital Management held 12,723,026 shares of Aclaris Therapeutics worth $66.9M as of Q3 2026.
- RA Capital Management left its Aclaris Therapeutics share count unchanged in Q3 2026.
- Aclaris Therapeutics made up 0.67% of RA Capital Management's portfolio in Q3 2026, its #32 holding.
- RA Capital Management first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 16 quarters since.
- RA Capital Management's Aclaris Therapeutics position peaked at $69.3M in Q4 2022.
- 163 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on RA Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.